Inovio Pharmaceuticals (NASDAQ:INO) announces the full enrollment of 40 healthy volunteers in a Phase 1 clinical trial of INO-4800, its COVID-19 DNA vaccine candidate.
All participants have received their first dose.
Preliminary immune response and safety data should be available in late
June. They will receive a second dose four weeks after the first.
Shares up 5% premarket on robust volume.
Moderna (NASDAQ:MRNA) (+7%) and iBio (NYSEMKT:IBIO) (+32%) are leading other COVID-19 vaccine players in premarket action. The former is poised to launch a Phase 2 study while the latter announced that it has the capacity to make 500M doses of its product, if approved.
Selected tickers: (NASDAQ:NVAX) (+2%), GlaxoSmithKline (NYSE:GSK) (+1%), Soligenix (NASDAQ:SNGX) (+6%), Dynavax (NASDAQ:DVAX) (+9%), Applied DNA Sciences (NASDAQ:APDN) (+1%)
https://seekingalpha.com/news/3565228-inovio-completes-enrollment-in-covidminus-19-vaccine-study-shares-up-5-premarket
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.